Navigation Links
New Hepatitis C Drugs Fuel Demand for Molecular IVD Products
Date:2/2/2017

ROCKVILLE, Md., Feb. 2, 2017 /PRNewswire/ -- Hepatitis C is a robustly growing market for both IVD and pharmaceutical players in the developed world. Hepatitis C pharmaceutical growth is hedged by pricing pressures as new players seek to undercut the market leader Gilead Sciences. Newer antivirals introduced first by Gilead in 2014 can cure even acute hepatitis C infections in many cases. The leading market barrier has been the price of therapy, but price cutting is expected eventually in order to maximize market penetration and as a result of competitive pressures. Antiviral treatment regimens are continued or concluded based on repeated testing of patient HCV levels or viral load.  Kalorama covered HCV testing markets along with a wide range of molecular diagnostic applications in its report, The World Market for Molecular Diagnostics, 7th EditionFind the report at: https://www.kaloramainformation.com/Molecular-Diagnostics-Edition-10595682/.

"The combination of Medicare eligibility for hepatitis C patients, higher screening activity and effective therapies has grown HCV viral load test volumes in the United States," said Emil Salazar, analyst for Kalorama Information in a recent blog post

Kalorama Information Logo. (PRNewsFoto/Kalorama Information) (PRNewsFoto/Kalorama Information)
Kalorama Information Logo. (PRNewsFoto/Kalorama Information) (PRNewsFoto/Kalorama Information)

The introduction of new, more effective therapies has coincided with rising hepatitis C patient volumes in U.S. healthcare. Hepatitis C is more prevalent among older U.S. individuals, particularly those of the "baby boomer" generation (born 1945-1965), than younger generations. According to one estimate from the National Health and Nutrition Examination Survey (NHANES), HCV can be found in between 3% and 5% of all U.S. individuals born in the 1950s. For comparison, HCV prevalence for individuals born in the 1940s and 1960s averaged roughly 2%. The higher rate of hepatitis C infection among baby boomers is believed to be a result of blood transfusion-transmitted infections (TTIs) and past intravenous drug use. Hepatitis screening of older patients has been implemented in much of U.S. healthcare to catch asymptomatic and mildly symptomatic cases.

Kalorama said the volume of viral load tests for hepatitis C accepted for payment under Medicare Part B rose from approximately 65,000 procedures in 2010 to nearly 190,000 procedures in 2015. Kalorama Information projects the number of HCV-infected U.S. individuals newly eligible for Medicare (aged 65 during the year) will increase from over 90,000 in 2015 to more than 170,000 in 2020. Medicare coverage of hepatitis C therapies has improved in the past several years, and some private insurers are also likely to follow suit for older patients more at risk of complications from disease progression.

Kalorama details more information in its blog piece on Hepatitis C testing.  http://www.kaloramainformation.com/Content/Blog/2017/01/27/New-Therapies-Risk-Factors-Drive-Hepatitis-C-Diagnostics

About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. Reports can be purchased through Kalorama's website and are also available on www.marketresearch.com and www.profound.com.  

We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog on our company website.  

Please link any media or news references to our reports or data to http://www.kaloramainformation.com/.

Press Contact:
Bruce Carlson
212 807 2262
bcarlson@marketresearch.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/new-hepatitis-c-drugs-fuel-demand-for-molecular-ivd-products-300401365.html


'/>"/>
SOURCE Kalorama Information
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. AbbVie Submits New Drug Application to U.S. FDA for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of All Major Genotypes of Chronic Hepatitis C
2. Arcturus Therapeutics Announces Collaboration with Takeda Pharmaceuticals to Develop RNA-based Therapeutics for the Treatment of Nonalcoholic Steatohepatitis (NASH)
3. Yisheng Biopharma Announces Completion of Phase I Clinical Study of a Novel Hepatitis B Vaccine with PIKA Adjuvant
4. Hepatitis E Diagnostic Tests Market Worth 60.4 Million USD by 2024: Fueled by Lack of Potable Water, Hepatitis E Hyperendemicity to Drive Growth, Reports TMR
5. Staaten wollen virale Hepatitis bis 2030 eliminieren
6. Governments on Track to Eliminate Viral Hepatitis by 2030
7. Global Hepatitis C Market and Competitive Landscape Report 2016-2020 - Research and Markets
8. Diplomat Celebrates World Hepatitis Month with National Multimedia Campaign
9. Global HCV Market: Gilead Sciences, AbbVie, J&J and Bristol-Myers Squibb Featured in 2016 Hepatitis C Virus Edition Report
10. Biotron Phase 2 Hepatitis C Trial Success
11. Eiger Announces Completion of Enrollment of Phase 2 LOWR HDV - 4 (LOnafarnib With Ritonavir in Hepatitis Delta Virus - 4) Study at Hannover Medical School
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/8/2019)... (PRWEB) , ... October 08, 2019 , ... ... year at Western Pennsylvania & Ohio Valley Oral & Maxillofacial Surgery. This cutting-edge ... from All-on-4® full arch dental implants to predictable jaw surgery with ...
(Date:10/8/2019)... ... October 08, 2019 , ... Fresno resident Regina Tanner has been selected by ... donor honoree. Regina will walk alongside the float, Light in the Darkness, during the ... and attorney, became a living organ donor in the fall of 2016 when her ...
(Date:10/8/2019)... ... ... A free, interactive event highlighting innovations and ideas helping people with Parkinson’s ... leaders, innovators and health experts, will display innovations that could help people with Parkinson’s ... CT on October 19 at the Coppertank Event Center in Austin, the event is ...
Breaking Medicine Technology:
(Date:10/15/2019)... ... 2019 , ... Nashville Fertility Center (NFC) is proud to announce that ... practice. In addition to treating general infertility, Dr. Van Heertum offers expertise in fertility ... forward to Dr. Van Heertum joining the practice and believes she is the perfect ...
(Date:10/11/2019)... ... October 11, 2019 , ... A Topping Out event was hosted ... by general contractors Adolfson & Peterson Construction. The event celebrated reaching the final height ... Road in Dallas. The first of its kind in Texas, STA’s facility will be ...
(Date:10/10/2019)... ... 10, 2019 , ... Caring.com, a leading senior care referral service with Family ... for Seniors to Live. All 50 states and 302 cities in the U.S. were ... development. , According to the U.S. Census Bureau , almost 20 million ...
(Date:10/8/2019)... ... 2019 , ... What unique insights can three former Surgeons General of the ... the nation? That question will be answered at ICAA 2019: Shaping the Future of ... event will take place October 10-12, 2019, at the Gaylord Palms Resort and Convention ...
(Date:10/8/2019)... ... October 08, 2019 , ... Dr. Amir HagShenas of Silicon Valley Smile Solutions ... relief from this common and treatable condition. Dr. HagShenas’ goal is to treat ... with uncomfortable symptoms, including tender and bleeding gums, and to prevent gum disease from ...
Breaking Medicine News(10 mins):